Hepatocellular carcinoma and liver transplantation: State of the art

Journal of Clinical and Translational Hepatology

Volumn 2, Issue 3, 2014, Pages 176-181

  Mancuso, Andrea ^a,b   Perricone, Giovanni ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

^b Azienda di Rilievo Nazionale e di Alta Specializzazione (ARNAS) Civico Benfratelli   (Italy)

Author keywords

Hepatocellular carcinoma; Liver transplantation; Milan criteria; Recurrence; Selection criteria; Sorafenib

Indexed keywords

EID: 84964026329     PISSN: 22250719     EISSN: 23108819     Source Type: Journal    
DOI: 10.14218/JCTH.2014.00013     Document Type: Review

References (86)

1. IARC; ; 2012.
2. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745–750. doi: 10.1056/NEJM199903113401001.
3. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74–108. doi: 10.3322/canjclin.55.2.74
4. Bruix J, Sherman M; American Association for the Study of Liver Diseases. Management of Hepatocellular Carcinoma: An Update. Hepatology 2011;53: 1020–1222. doi: 10.1002/hep.24199.
5. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, et al. Management of Hepatocellular Carcinoma in Japan: Consensus-Based Clinical Practice Guidelines Proposed by the Japan Society of Hepatology (JSH) 2010 Updated Version. Dig Dis 2011;29:339–364. doi: 10.1159/000327577.
6. European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC Clinical Practice Guidelines: Management of Hepatocellular Carcinoma. J Hepatol 2012;56:908–943.
7. Sangiovanni A, Prati GM, Fasani P, Ronchi G, Romeo R, Manini M, et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006;43:1303–1310. doi: 10.1002/hep.21176.
8. Ioannou GN, Bryson CL, Weiss NS, Miller R, Scott JD, Boyko EJ. The prevalence of cirrhosis and hepatocellular carcinoma in patients with human immunodeficiency virus infection. Hepatology 2013;57:249–257. doi: 10.1002/hep.25800.
9. Sahasrabuddhe VV, Shiels MS, McGlynn KA, Engels EA. The risk of hepatocellular carcinoma among individuals with acquired immunodeficiency syndrome in the United States. Cancer 2012;118:6226–6233. doi: 10.1002/cncr.27694.
10. Merchante N, Merino E, López-Aldeguer J, Jover F, Delgado-Fernández M, Galindo MJ, et al. Increasing incidence of hepatocellular carcinoma in HIV-infected patients in Spain. Clin Infect Dis 2013;56:143–150. doi: 10.1093/cid/cis777.
11. Mancuso A, Rigano P, Renda D, Di Salvo V, Pignatti CB, Guddo F, et al. Hepatocellular carcinoma on cirrhosis-free liver in a HCV-infected thalasse-mic. Am J Hematol 2005;78:158–159. doi: 10.1002/ajh.20289
12. Mancuso A, Sciarrino E, Renda MC, Maggio A. A prospective study of hepatocellular carcinoma incidence in thalassemia. Hemoglobin 2006;30: 119–124. doi: 10.1080/03630260500455565
13. Mancuso A. Hepatocellular carcinoma in thalassemia: A critical review. World J Hepatol 2010;2:171–174.
14. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379: 1245–1255. doi: 10.1016/S0140-6736(11)61347-0.
15. Mazzaferro V, Chun YS, Poon RT, Schwartz ME, Yao FY, Marsh JW, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol 2008;15: 1001–1007. doi: 10.1245/s10434-007-9559-5.
16. Mazzaferro V. Selection criteria for HCC and downstaging procedures. In EASL postgraduate course. Transplantation & the liver. EASL international liver congress, 2013.
17. Adam R, Karam V, Delvart V, O’Grady J, Mirza D, Klempnauer J, et al. Evolution of indications and results of liver transplantation in Europe. A report from the European Liver Transplant Registry (ELTR). J Hepatol 2012; 57:675–688. doi: 10.1016/j.jhep.2012.04.015.
18. OPTN/SRTR. Annual Report; 2011.
19. China Liver Transplant Registry. 2012. http://www.ilts.org/uploads/4_wang.pdf.
20. Iwatsuki S, Starzl TE, Sheahan DG, Yokoyama I, Demetris AJ, Todo S, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991;214:221–228. doi: 10.1097/00000658-199109000-00005.
21. Iwatsuki S, Esquivel CO, Gordon RD, Shaw Jr BW, Starzl TE, Shade RR, et al. Liver transplantation for fulminant hepatic failure. Semin Liver Dis 1985;5: 325–328. doi: 10.1055/s-2008-1040628.
22. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996;334:693–699.
23. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999;30:1434–1440. doi: 10.1002/hep.510300629.
24. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999;19:311–322. doi: 10.1055/s-2007-1007120.
25. Bismuth H, Chiche L, Adam R, Castaing D, Diamond T, Dennison A. Liver resection versus transplantation for hepatocellular carcinoma in cirrhosis. Ann Surg 1993;218:145–151. doi: 10.1097/00000658-199308000-00005.
26. Jonas S, Bechstein WO, Steinmüller T, Herrmann M, Radke C, Berg T, et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001; 33:1080–1086. doi: 10.1053/jhep.2001.23561.
27. Mazzaferro V, Bhoori S, Sposito C, Bongini M, Langer M, Miceli R, et al. Milan criteria in liver transplantation for hepatocellular carcinoma: an evidence-based analysis of 15 years of experience. Liver Transpl 2011;17 (Suppl 2): S44–57. doi: 10.1002/lt.22365.
28. www.eltr.org/, accessed Nov 2011.
29. http://www.ustransplant.org/annual_reports/current/, accessed Nov 2011.
30. Llovet JM, Brú C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329–338. doi: 10.1055/s-2007-1007122.
31. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008;100:698–711. doi: 10.1093/jnci/djn134.
32. Freeman Jr RB, Wiesner RH, Harper A, McDiarmid SV, Lake J, Edwards E, et al. UNOS/OPTN Liver Disease Severity Score, UNOS/OPTN Liver and Intestine, and UNOS/OPTN Pediatric Transplantation Committees. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002;8:851–858. doi: 10.1053/jlts.2002.35927.
33. Clavien PA, Lesurtel M, Bossuyt PM, Gores GJ, Langer B, Perrier A, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012;13:e11–22. doi: 10.1016/S1470-2045(11)70175-9.
34. Marsh JW, Dvorchik I, Bonham CA, Iwatsuki S. Is the pathologic TNM staging system for patients with hepatoma predictive of outcome? Cancer 2000;88: 538–543. doi: 10.1002/(SICI)1097-0142(20000201)88:3<538::AID-CNCR7>3.0.CO;2-H.
35. Marsh JW, Dvorchik I. Liver organ allocation for hepatocellular carcinoma: are we sure? Liver Transpl 2003;9:693–696. doi: 10.1053/jlts.2003.50086.
36. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, Camerini T, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, explora-tory analysis. Lancet Oncol 2009;10:35–43. doi: 10.1016/S1470-2045(08)70284-5.
37. Prasad KR, Young RS, Burra P, Zheng SS, Mazzaferro V, Moon DB, et al. Summary of candidate selection and expanded criteria for liver transplantation for hepatocellular carcinoma: a review and consensus statement. Liver Transpl 2011;17 (Suppl 2):S81–89. doi: 10.1002/lt.22380.
38. Yao FY, Ferrell L, Bass NM, Watson JJ, Bacchetti P, Venook A, et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001;33:1394–1403. doi: 10.1053/jhep.2001.24563
39. Yao FY, Xiao L, Bass NM, Kerlan R, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 2007;7:2587–2596. doi: 10.1111/j.1600-6143.2007.01965.x.
40. Raj A, McCall J, Gane E. Validation of the ‘‘Metroticket’’ predictor in a cohort of patients transplanted for predominantly HBV-related hepatocellular carci-noma. J Hepatol 2011;55:1063–1068. doi: 10.1016/j.jhep.2011.01.052.
41. Yao FY, Breitenstein S, Broelsch CE, Dufour JF, Sherman M. Does a patient qualify for liver transplantation after the down-staging of hepatocellular carcinoma? Liver Transpl 2011;17 (Suppl 2):S109–116. doi: 10.1002/lt.22335.
42. Pomfret EA, Washburn K, Wald C, Nalesnik MA, Douglas D, Russo M, et al. Report of a national conference on liver allocation in patients with hepatocellular carcinoma in the United States. Liver Transpl 2010;16:262– 278. doi: 10.1002/lt.21999.
43. Mazzaferro V, Battiston C, Perrone S, Pulvirenti A, Regalia E, Romito R, et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004;240:900–909. doi: 10.1097/01.sla.0000143301.56154.95
44. Lu DS, Yu NC, Raman SS, Lassman C, Tong MJ, Britten C, et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005;41:1130–1137. doi: 10.1002/hep.20688.
45. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997;226:688–701; discussion 701–703. doi: 10.1097/00000658-199712000-00006
46. Decaens T, Roudot-Thoraval F, Bresson-Hadni S, Meyer C, Gugenheim J, Durand F, et al. Impact of pretransplantation transarterial chemoemboliza-tion on survival and recurrence after liver transplantation for hepatocellular carcinoma. Liver Transpl 2005;11:767–775. doi: 10.1002/lt.20418
47. Porrett PM, Peterman H, Rosen M, Sonnad S, Soulen M, Markmann JF, et al. Lack of benefit of pre-transplant locoregional hepatic therapy for hepatocel-lular cancer in the current MELD era. Liver Transpl 2006;12:665–673. doi: 10.1002/lt.20636
48. Llovet JM, Mas X, Aponte JJ, Fuster J, Navasa M, Christensen E, et al. Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. Gut 2002;50:123–128. doi: 10.1136/gut.50.1.123
49. Mazzaferro V, Majno P. Principles for the best multidisciplinary meetings. Lancet Oncol 2011;12:323–325. doi: 10.1016/S1470-2045(11)70010-9.
50. Yao FY, Kerlan RK, Hirose R, Davern TJ, Bass NM, Feng S, et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 2008;48:819– 827. doi: 10.1002/hep.22412.
51. Ravaioli M, Grazi GL, Piscaglia F, Trevisani F, Cescon M, Ercolani G, et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 2008;8: 2547–2557. doi: 10.1111/j.1600-6143.2008.02409.x.
52. De Carlis L, Di Sandro S, Giacomoni A, Slim A, Lauterio A, Mangoni I, et al. Beyond the Milan criteria: what risks for patients with hepatocellular carcinoma progression before liver transplantation? J Clin Gastroenterol 2012;46:78–86. doi: 10.1097/MCG.0b013e31822b36f6.
53. Mela M, Mancuso A, Burroughs AK. Review article: hepatocellular carcinoma: indications for liver transplantation. Aliment Pharmacol Ther 2003;17 (Suppl 2):130–137. doi: 10.1046/j.1365-2036.17.s2.16.x.
54. Duvoux C, Roudot-Thoraval F, Decaens T, Pessione F, Badran H, Piardi T, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012;143:986–994 e983; quiz e914–985. doi: 10.1053/j.gas-tro.2012.05.052.
55. Trotter JF, Wachs M, Everson GT, Kam I. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 2002;346:1074–1082.
56. Clavien PA, Petrowsky H, DeOliveira ML, Graf R. Strategies for safer liver surgery and partial liver transplantation. N Engl J Med 2007;356:1545– 1559.
57. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519–524. doi: 10.1053/jhep.2002.32089.
58. Siegler M, Simmerling MC, Siegler JH, Cronin 2nd DC. Recipient deaths during donor surgery: a new ethical problem in living donor liver transplantation (LDLT). Liver Transpl 2006;12:358–360. doi: 10.1002/lt.20670.
59. Ghobrial RM, Freise CE, Trotter JF, Tong L, Ojo AO, Fair JH, et al. Donor morbidity after living donation for liver transplantation. Gastroenterology 2008;135:468–476. doi: 10.1053/j.gastro.2008.04.018.
60. Browns Jr RS. Live donors in liver transplantation. Gastroenterology 2008; 134:1802–1813. doi: 10.1053/j.gastro.2008.02.092.
61. Lo CM, Fan ST, Liu CL, Chan SC, Ng IO, Wong J. Living donor versus deceased donor liver transplantation for early irresectable hepatocellular carcinoma. Br J Surg 2007;94:78–86.
62. Fisher RA, Kulik LM, Freise CE, Lok AS, Shearon TH, Brown Jr RS, et al. A2ALL Study Group. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 2007;7:1601– 1608.
63. Sarasin FP, Majno PE, Llovet JM, Bruix J, Mentha G, Hadengue A. Living donor liver transplantation for early hepatocellular carcinoma: a lifeexpectancy and cost–effectiveness perspective. Hepatology 2001;33:1073–1079.
64. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. SHARP Investigators Study Group. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378–390.
65. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocel-lular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009;10:25–34. doi: 10.1016/S1470-2045(08)70285-7.
66. Pfeiffenberger J, Koschny R, Hoffmann K, Mehrabi A, Schmitz A, Radeleff B, et al. Sorafenib treatment is save and may affect survival of recurrent hepatocellular carcinoma after liver transplantation. Langenbecks Arch Surg 2013;398:1123–1128. doi: 10.1007/s00423-013-1114-1.
67. Waghray A, Balci B, El-Gazzaz G, Kim R, Pelley R, Narayanan Menon KV, et al. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation. Clin Transplant 2013:27:555–561. doi: 10.1111/ctr.12150.
68. Sposito C, Mariani L, Germini A, Flores Reyes M, Bongini M, Grossi G, et al. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study. J Hepatol 2013;59:59–66. doi: 10.1016/j.jhep.2013.02.026.
69. Sotiropoulos GC, Nowak KW, Fouzas I, Vernadakis S, Kykalos S, Klein CG, et al. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation. Transplant Proc 2012;44:2754–2756. doi: 10.1016/j.trans-proceed.2012.09.022.
70. Zavaglia C, Airoldi A, Mancuso A, Vangeli M, Viganò R, Cordone G, et al. Adverse events affect sorafenib efficacy in patients with recurrent hepato-cellular carcinoma after liver transplantation: experience at a single center and review of the literature. Eur J Gastroenterol Hepatol 2013;25:180–186.
71. Vitale A, Boccagni P, Kertusha X, Zanus G, D’Amico F, Lodo E, et al. Sorafenib for the treatment of recurrent hepatocellular carcinoma after liver trans-plantation? Transplant Proc 2012;44:1989–91. doi: 10.1016/j.transpro-ceed.2012.06.046.
72. Staufer K, Fischer L, Seegers B, Vettorazzi E, Nashan B, Sterneck M. High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation. Transpl Int 2012;25:1158–64. doi: 10.1111/j.1432-2277.2012.01540.x.
73. Weinmann A, Niederle IM, Koch S, Hoppe-Lotichius M, Heise M, Düber C, et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplanta-tion. Dig Liver Dis 2012;44:432–437. doi: 10.1016/j.dld.2011.12.009.
74. Pfiffer TE, Seehofer D, Nicolaou A, Neuhaus R, Riess H, Trappe RU. Recurrent hepatocellular carcinoma in liver transplant recipients: parameters affecting time to recurrence, treatment options and survival in the sorafenib era. Tumori 2011;97:436–441. doi: 10.1700/950.10394.
75. Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl 2012;18:45–52. doi: 10.1002/lt.22434.
76. Tan WF, Qiu ZQ, YU Y, Ran RZ, Yi B, Lau WY, et al. Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation. Acta Pharmacol Sin 2010;31:1643– 1648. doi: 10.1038/aps.2010.124.
77. Kim R, El-Gazzaz G, Tan A, Elson P, Byrne M, Chang YD, et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010;79:62–66. doi: 10.1159/000319548.
78. Yoon DH, Ryoo BY, Ryu MH, Lee SG, Hwang S, Suh DJ, et al. Jpn Sorafenib for recurrent hepatocellular carcinoma after liver transplantation. J Clin Oncol 2010;40:768–773. doi: 10.1093/jjco/hyq055.
79. Valdivieso A, Bustamante J, Gastaca M, Uriarte JG, Ventoso A, Ruiz P, et al. Management of hepatocellular carcinoma recurrence after liver transplantation. Transplant Proc 2010;42:660–662. doi: 10.1016/j.transproceed.2010.02.014.
80. Feun LG, Levi D, Moon J, Nishida S, Island E, Selvaggi G, et al. Sorafenib in hepatocellular carcinoma (HCC) patients after liver transplantation. J Clin Oncol 2009;27 (suppl 20):e15579.
81. Derancy S, Romano O., Lorho R., et al. Tolerability and efficacy ofsorafennib in recurrent hepatocellularcarcinoma after livertransplantation: a case-control study. Abstract book EASL 2010.
82. Toso C, Mentha G, Majno P. Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence. J Hepatol 2013;59:3–5. doi: 10.1016/j.jhep.2013.03.029.
83. Mancuso A, Mazzarelli C, Perricone G, Zavaglia C. Sorafenib efficacy for treatment of HCC recurrence after Liver Transplantation is an open issue. J Hepatol 2014;60:681. doi: 10.1016/j.jhep.2013.10.030.
84. Sposito C, Mazzaferro V. Reply to ‘‘Sorafenib efficacy for treatment of HCC recurrence after Liver Transplantation is an open issue’’. J Hepatol 2014;60: 682–683. doi: 10.1016/j.jhep.2013.10.032.
85. Mancuso A, Airoldi A, Vigano R, Pinzello G. Fatal gastric bleeding during sorafenib treatment for hepatocellular carcinoma recurrence after liver transplantation. Dig Liver Dis 2011;43:754. doi: 10.1016/j.dld.2011.04.022.
86. Mancuso, Zavaglia C, Bai F, Puoti M, Belli L. Sorafenib hepatotoxicity seems to be enhanced by HAARTS interaction during treatment of advanced hepatocelluler carcinoma in HIV-infected patients. Aliment Pharmacol Ther 2013;38:1414–1416. doi: 10.1111/apt.12536.